THE IMPACT OF MASLD ON AUTOIMMUNE HEPATITIS OUTCOMES: A NATIONWIDE ANALYSIS OF 2880 RECORDS.

IF 3 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Clinical and Translational Gastroenterology Pub Date : 2025-09-12 DOI:10.14309/ctg.0000000000000912

Yassine Kilani, Mohammad Aldiabat, Kym Yves T Sirilan, Ahmad Basil Nasir, Mahmoud Y Madi, Wing-Kin Syn

{"title":"THE IMPACT OF MASLD ON AUTOIMMUNE HEPATITIS OUTCOMES: A NATIONWIDE ANALYSIS OF 2880 RECORDS.","authors":"Yassine Kilani, Mohammad Aldiabat, Kym Yves T Sirilan, Ahmad Basil Nasir, Mahmoud Y Madi, Wing-Kin Syn","doi":"10.14309/ctg.0000000000000912","DOIUrl":null,"url":null,"abstract":"Background: Despite the growing recognition of autoimmune hepatitis (AIH) - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) overlap, studies today are limited by small sample sizes. This study aimed to investigate the impact of MASLD on the outcomes of patients with AIH using large-scale real world data.Methods: This cohort study used the TriNetX research network to identify U.S. adults (≥18 years) with AIH. Patients were stratified into those with MASLD (AIH-MASLD cohort), and controls (AIH without MASLD). Propensity score matching (1:1) between AIH-MASLD and controls accounted for demographics, comorbidities, and treatments. Outcomes were classified as short-term (within 1 year after diagnosis) or long-term (within 10 years) outcomes.Results: Among 4,798 records with AIH, 1,440 AIH-MASLD patients were propensity matched with 1,440 controls. AIH-MASLD patients demonstrated reduced one-year odds of all-cause mortality (HR = 0.66, 95%CI: 0.44 - 0.98), and immunosuppressive medication use (HR = 0.69, 95%CI: 0.63 - 0.76), along with increased 10-year odds of cirrhosis (HR = 1.22, 95%CI: 1.06 - 1.40) and hepatocellular carcinoma (HR = 2.03, 95%CI: 1.09 - 3.78) compared to controls.Conclusions: In summary, our study using real-world evidence showed a significant association between MASLD and worse clinical outcomes in patients with AIH. Future efforts should be targeted towards facilitating early detection and management of MASLD in AIH patients.","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000912","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Despite the growing recognition of autoimmune hepatitis (AIH) - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) overlap, studies today are limited by small sample sizes. This study aimed to investigate the impact of MASLD on the outcomes of patients with AIH using large-scale real world data.

Methods: This cohort study used the TriNetX research network to identify U.S. adults (≥18 years) with AIH. Patients were stratified into those with MASLD (AIH-MASLD cohort), and controls (AIH without MASLD). Propensity score matching (1:1) between AIH-MASLD and controls accounted for demographics, comorbidities, and treatments. Outcomes were classified as short-term (within 1 year after diagnosis) or long-term (within 10 years) outcomes.

Results: Among 4,798 records with AIH, 1,440 AIH-MASLD patients were propensity matched with 1,440 controls. AIH-MASLD patients demonstrated reduced one-year odds of all-cause mortality (HR = 0.66, 95%CI: 0.44 - 0.98), and immunosuppressive medication use (HR = 0.69, 95%CI: 0.63 - 0.76), along with increased 10-year odds of cirrhosis (HR = 1.22, 95%CI: 1.06 - 1.40) and hepatocellular carcinoma (HR = 2.03, 95%CI: 1.09 - 3.78) compared to controls.

Conclusions: In summary, our study using real-world evidence showed a significant association between MASLD and worse clinical outcomes in patients with AIH. Future efforts should be targeted towards facilitating early detection and management of MASLD in AIH patients.

查看原文本刊更多论文

masld对自身免疫性肝炎结局的影响：全国2880例记录分析

背景：尽管越来越多的人认识到自身免疫性肝炎(AIH) -代谢功能障碍相关脂肪变性肝病（MASLD）重叠，但目前的研究受到小样本量的限制。本研究旨在利用大规模真实世界数据调查MASLD对AIH患者预后的影响。方法：本队列研究使用TriNetX研究网络识别美国成人（≥18岁）AIH。患者被分为MASLD患者（AIH-MASLD队列）和对照组（AIH无MASLD）。AIH-MASLD和对照组之间的倾向评分匹配（1:1）考虑了人口统计学、合并症和治疗。结果分为短期（诊断后1年内）和长期（10年内）结果。结果：在4798例AIH患者中，1440例AIH- masld患者与1440例对照组倾向匹配。与对照组相比，AIH-MASLD患者的1年全因死亡率（HR = 0.66, 95%CI: 0.44 - 0.98）和免疫抑制药物使用（HR = 0.69, 95%CI: 0.63 - 0.76）降低，10年肝硬化（HR = 1.22, 95%CI: 1.06 - 1.40）和肝细胞癌（HR = 2.03, 95%CI: 1.09 - 3.78）发生率增加。结论：总之，我们使用真实世界证据的研究表明，AIH患者的MASLD与较差的临床结果之间存在显著关联。未来的努力应着眼于促进AIH患者的MASLD的早期发现和管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

7.00

自引率

0.00%

发文量

114

审稿时长

16 weeks

期刊介绍： Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease. Colon and small bowel Endoscopy and novel diagnostics Esophagus Functional GI disorders Immunology of the GI tract Microbiology of the GI tract Inflammatory bowel disease Pancreas and biliary tract Liver Pathology Pediatrics Preventative medicine Nutrition/obesity Stomach.